Core Viewpoint - ChemoMetec has adjusted its revenue and EBITDA guidance for the financial year 2025/26 due to several market challenges, despite a strong competitive position in cell counting automation [1][2]. Group 1: Market Challenges - The North American market for cell and gene therapy has been impacted by government lockdowns and geopolitical uncertainties, leading to prolonged decision-making processes among customers [5]. - The implementation of automation in the production of cell and gene therapies has proven to be more time-consuming than anticipated, causing delays in validations and decisions [5]. - Increased interest in the XcytoMatic platform has resulted in a slowdown in sales of NC instruments and associated consumables [5]. Group 2: Financial Adjustments - Revenue is now expected to be in the range of DKK 490-520 million, a decrease from the previously announced DKK 565-580 million [2]. - EBITDA is projected to be between DKK 260-285 million, down from the earlier guidance of DKK 320-335 million [2]. Group 3: Competitive Position - ChemoMetec continues to see a growing number of automation projects and confirms that its XcytoMatic products remain attractive and competitive in the market [1]. - The upcoming introduction of the new software platform XM Octopus is expected to further strengthen ChemoMetec's market position [1].

Group 1 - The company is focusing on expanding proteome coverage by targeting the detection of 18 to 20 amino acids and increasing sequencing read lengths on the Proteus prototype [1] - The list price for the Proteus has been set at $425,000 to align with academic grant cycles and assist potential customers with long-term capital budgeting [1] Group 2 - The strategic focus has shifted towards building a robust publication pipeline, with 5 manuscripts submitted in 2025 to showcase technology utility in clinical proteomics and pathogen detection [2] - The instrument placement program has successfully secured 17 new customers, which helps maintain user engagement and generate consumable revenue without requiring upfront capital [2] Group 3 - Performance in Q4 2025 was affected by capital spending headwinds, including uncertainties in NIH funding and customer hesitation regarding the next-generation platform [3] - Management is transitioning 2026 into a 'market preparation' year, prioritizing the upcoming Proteus launch over maximizing near-term Platinum Pro capital sales [3] - Revenue guidance for 2026 is approximately $1 million, reflecting a shift towards consumable utilization and service revenue rather than new hardware sales [3] - The commercial launch of Proteus is on track for the end of 2026, with prototype systems currently deployed for internal R&D and manufacturing scale-up [3] - Financial guidance indicates total cash usage of $93 million or less, with a balance sheet designed to fund operations into the second quarter of 2028 [3] - A 25% increase in consumable kit volume is expected in 2026 as the installed base matures and new placement-program users begin running experiments [3] - Future margin expansion is anticipated due to the cost-effectiveness of the Proteus passive nano-well architecture compared to current CMOS-based chips [3]

Core Insights - ChemoMetec reported a revenue growth of 22% to DKK 495.6 million for the financial year 2024/25, with EBITDA increasing by 39% to DKK 258.0 million, driven by strong sales across instruments, consumables, and services [1][8]. Financial Performance - Revenue for 2024/25 reached DKK 495.6 million, with a 22% increase compared to the previous year, and this growth was consistent in both Danish kroner and at constant exchange rates [8]. - The EBITDA for the year was DKK 258.0 million, up from DKK 186.2 million in 2023/24, primarily due to increased revenue without a corresponding rise in costs, despite non-recurring restructuring costs of DKK 11.8 million impacting the results [8]. - The EBITDA margin improved to 52% from 46% in the previous year, and the profit for the year rose by DKK 50.1 million to DKK 186.4 million [8]. - The company proposed a dividend of DKK 7.0 per share, totaling DKK 121.8 million for the financial year [8]. Product Development and Market Strategy - ChemoMetec is focusing on launching new high-tech XcytoMatic products, with the XcytoMatic 40 targeting the bioprocessing market and the XcytoMatic 30 and 50 aimed at automation needs in cell and gene therapy [2][4]. - The company is confident in its market position within the automation sector and plans to accelerate marketing efforts for new products while continuing to develop additional solutions like the Sample Management System [3][4]. - The validation and decision-making process for the new XcytoMatic instruments is expected to be lengthy, requiring patience to realize their full potential [5]. Market Guidance - For the financial year 2025/26, ChemoMetec anticipates revenue between DKK 545 million and DKK 565 million, with EBITDA projected in the range of DKK 295 million to DKK 315 million [7]. Geographic Revenue Distribution - In the 2024/25 financial year, 59% of ChemoMetec's revenue was generated from the USA/Canada, 32% from Europe, and 9% from the rest of the world, showing no change from the previous year [8]. Conference Call Announcement - A conference call is scheduled for 12 September 2025, where the CEO and CFO will present the annual report for 2024/25 [9].